Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. by Leggas, M et al.
MOLECULAR AND CELLULAR BIOLOGY, Sept. 2004, p. 7612–7621 Vol. 24, No. 17
0270-7306/04/$08.000 DOI: 10.1128/MCB.24.17.7612–7621.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Mrp4 Confers Resistance to Topotecan and Protects the Brain
from Chemotherapy
Markos Leggas,1 Masashi Adachi,1 George L. Scheffer,2 Daxi Sun,1 Peter Wielinga,3 Guoqing Du,1
Kelly E. Mercer,1 Yanli Zhuang,1 John C. Panetta,1 Brad Johnston,1 Rik J. Scheper,2
Clinton F. Stewart,1 and John D. Schuetz1*
Department of Pharmaceutical Sciences, St. Jude Children’s Research Hospital, Memphis, Tennessee,1
and Department of Pathology, VU Medical Center,2 and Division of Molecular Biology, The
Netherlands Cancer Institute,3 Amsterdam, The Netherlands
Received 6 April 2004/Returned for modification 29 May 2004/Accepted 12 June 2004
The role of the multidrug resistance protein MRP4/ABCC4 in vivo remains undefined. To explore this role,
we generated Mrp4-deficient mice. Unexpectedly, these mice showed enhanced accumulation of the anticancer
agent topotecan in brain tissue and cerebrospinal fluid (CSF). Further studies demonstrated that topotecan
was an Mrp4 substrate and that cells overexpressing Mrp4 were resistant to its cytotoxic effects. We then used
new antibodies to discover that Mrp4 is unique among the anionic ATP-dependent transporters in its dual
localization at the basolateral membrane of the choroid plexus epithelium and in the apical membrane of the
endothelial cells of the brain capillaries. Microdialysis sampling of ventricular CSF demonstrated that
localization of Mrp4 at the choroid epithelium is integral to its function in limiting drug penetration into the
CSF. The topotecan resistance of cells overexpressing Mrp4 and the polarized expression of Mrp4 in the
choroid plexus and brain capillary endothelial cells indicate that Mrp4 has a dual role in protecting the brain
from cytotoxins and suggest that the therapeutic efficacy of central nervous system-directed drugs that are
Mrp4 substrates may be improved by developing Mrp4 inhibitors.
The brain is protected by two permeability barriers, the
blood-brain barrier and the blood-cerebrospinal fluid (CSF)
barrier (14, 32). The blood-CSF barrier is anatomically defined
by the choroid plexus, located in the lateral, third, and fourth
ventricles. Anionic and cationic transporters expressed by the
choroid plexus epithelial cells are thought to prevent entry by
certain compounds. The mechanism of this function differs
depending on the selective expression of the transporters on
the apical versus the basolateral surface of the cells. The ATP-
binding cassette (ABC) transporter Mrp1 localizes in the ba-
solateral membrane of choroid plexus epithelial cells (30, 46)
but is not expressed in endothelial cells in the brain capillaries.
The endothelial cells of the brain’s capillaries are tightly
joined to form a hydrophobic permeability barrier (32) termed
the blood-brain barrier. Pgp expression in these cells limits the
movement of hydrophobic cationic drugs from the blood into
the brain (36, 42, 43). However, in vitro, these capillary endo-
thelial cells also transport organic anions unidirectionally to-
ward the capillary lumen in an energy-dependent fashion (5,
25, 41). Therefore, the capillary endothelial cells appear to
express an unidentified anionic ABC transporter. Currently, it
is unknown whether an anionic ABC transporter is expressed
at functional levels in vivo in the endothelium of brain capillaries.
The ABC transporter Mrp4, originally described as a nucle-
otide transporter (37), is known to transport a diverse array of
compounds (2, 7, 34) and is capable of transporting organic
anions as well as antiviral and antiretroviral compounds that
do not easily penetrate the central nervous system (CNS) (2, 3,
9, 27, 37). Mrp4 expression was previously demonstrated on
the basolateral membrane of the prostate gland and the apical
membrane of the kidney (21, 44). Studies in cultured epithelial
cells have demonstrated basolateral localization of Mrp4 (22).
Transporters typically route to one surface in polarized cells.
For instance, the Mrp (ABCC) subfamily members localize to
either the basolateral or apical membrane, but not to both.
MRP1 is restricted to the basolateral membrane of the choroid
plexus and intestine, whereas MRP2 is found on the apical
membrane in the intestine and liver (26, 29). Mrp4 might be
unique among the Mrp transporters in having cell- or tissue-
dependent polarized expression, but the biological importance
of this unique ability to localize either apically or basolaterally
remains unknown.
We have developed Mrp4 knockout mice, and here we re-
port their first use to show that Mrp4 is expressed in the lumen
of brain capillaries and in the basolateral membrane in the
choroid plexus epithelium. In vivo, Mrp4 restricts topotecan
movement from the blood into the CSF and from the capillar-
ies into the brain tissue by virtue of its unique ability to traffic
to either the apical or basolateral membrane. We further show
that Mrp4 overexpression confers resistance to the camptoth-
ecin topotecan. These studies have specific therapeutic impli-
cations for targeting the CNS that might harbor tumors but
have more general implications in CNS therapy because of the
expanding array of important drugs known to be transported
by Mrp4.
MATERIALS AND METHODS
Choroid tissues. Human choroid plexus tissue was obtained from the tissue
bank of St. Jude Children’s Research Hospital and from commercially available
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human tissue arrays (ResGen/Invitrogen). Mouse tissues were dissected from the
lateral and fourth ventricles with a stereo microscope.
Immunohistochemistry reagents. 3-Diaminobenzidine tetrahydrochloride
(DAB), avidin-biotin blocking reagents, hematoxylin, and streptavidin-horserad-
ish peroxidase were obtained from DakoCytomation. Goat serum, rabbit serum,
biotin-labeled goat anti-rabbit and rabbit anti-rat immunoglobulin antibodies,
and rabbit immunoglobulin G were from Vectorlabs. Hydrogen peroxide (30%),
an aminoethyl carbazole kit, and rat immunoglobulin G were from Sigma. Horse-
radish peroxidase-labeled goat anti-rat immunoglobulin antiserum was obtained
from Santa Cruz Biotech. Citrate buffer came from Zymed Laboratories.
Construction and genotyping of the targeting vector. A 3 fragment from the
mouse Mrp4 cDNA was used to screen a bacterial artificial chromosome genomic
library; one clone (18832) was selected for development of the targeting vector.
The exon and intron junctions of the mouse Mrp4 gene (23) were used in
developing the targeting vector. The 5 arm consisted of a 2.7-kb BamHI/XhoI
fragment 5 of exon 27 that was ligated into the pKONTKV1901 vector (Strat-
agene). The 3 arm was generated by PCR with the bacterial artificial chromo-
some clone as the template. One primer contained an artificial XhoI site and stop
codons engineered into exon 27. The other primer contained a SalI site in exon
28. These two primers were used to amplify a 7-kb fragment that was then
subcloned into the SalI site of the pKONTV1901 vector. The fragment was
verified by DNA sequence analysis. The targeting vector was linearized by NotI
and then electroporated into 129/SVJ-derived embryonic stem (ES) cells.
Genomic DNA from 487 ES clones that survived 2 weeks of G418 selection was
screened first by PCR analysis and subsequently by Southern blot analysis after
digestion with BamHI. Twenty-four clones had undergone the correct homolo-
gous recombination. Chimeric mice were generated by injecting independently
isolated ES clones into C57BL/6 blastocysts. All experiments were approved by
the St. Jude Children’s Research Hospital animal care and use committee.
Antibody generation, immunoblotting, and immunohistochemistry. The poly-
clonal anti-mouse Mrp4 antiserum (Mrp4-mp) was created by immunizing rab-
bits with a keyhole limpet hemocyanin-conjugated 17-residue peptide (NTS
NGQ PSA LTI FET AL) derived from the C terminus of the murine Mrp4/
Abcc4 sequence (23) and purified by peptide affinity column. We also used an
anti-human MRP4 antibody (Mrp4-hp) that was cross-reactive with a homolo-
gous region of mouse Mrp4 (2, 37).
Antibodies were generated by constructing a fusion gene encoding the Esch-
erichia coli maltose-binding protein and a fragment of human MRP4 (amino
acids 372 to 431 [FP M4I]) in the pMAL-c vector as described previously (11, 35).
The immunization and fusion protocols have been described previously (11, 35).
Briefly, a 12-week-old female Wistar rat was injected with approximately 100 g
of the fusion protein. Three booster injections were given. Cells obtained from
draining popliteal lymph nodes and the spleen of the rat were fused with Sp20
mouse myeloma cells. Supernatants were screened for hybridoma cells contain-
ing monoclonal antibodies on enzyme-linked immunosorbent assay plates coated
with specific fusion protein and, as a control, on plates coated with an irrelevant
fusion protein. Several hybridomas produced antibodies that reacted with the
fusion protein under Western blot conditions.
Two antibodies, M4I-10 and M4I-80, were selected for further analysis. Their
isotype was determined by using isotype-specific second-step reagents (Nordic,
Tilburg, The Netherlands). The reactivity of these monoclonal antibodies to the
approximately 180,000-kDa full-length Mrp4 was shown by Western blot analysis
with fractions of Mrp4-overexpressing HEK 293 cells (49). The monoclonal
antibodies also reacted with the mouse orthologue, Mrp4, in Western blot anal-
ysis of kidney protein fractions from wild-type and Mrp/ mice. Antibody
binding was detected by using horseradish peroxidase-labeled rabbit anti-rat
immunoglobulin antiserum (Dako, Copenhagen, Denmark) and 5-amino-2-hy-
droxybenzoic acid (Merck, Darmstadt, Germany) with 0.02% H2O2 as a chro-
mogen.
Lysates and/or crude membrane fractions of cell lines and tissues were pre-
pared and analyzed as previously described (2, 37). Protein concentration was
determined with the Bio-Rad protein assay (8) obtained from Bio-Rad Labora-
tories (Hercules, Calif.). Proteins were size fractionated on a 7% polyacrylamide
gel and transferred to a nitrocellulose membrane by electroblotting. The mem-
brane was blocked and incubated with the primary antibody at the appropriate
dilution and then with the secondary horseradish peroxidase-labeled anti-rat
immunoglobulin antiserum (Dako). Enhanced chemiluminescence (Amersham)
was used to detect immunoreactive protein. Ponceau S staining was used to
ensure equivalent protein loading.
Mrp4 expression was analyzed immunohistochemically in 4-m sections of
formalin-fixed, paraffin-embedded tissue. The tissue sections were cleared of
paraffin, rehydrated with xylene and ethanol, and then boiled in a pressure
cooker in 0.1 M citrate buffer (pH 6.0) to reconstitute antigenicity. The samples
were treated with peroxidases, avidin, and biotin to block nonspecific reaction.
The tissue sections were incubated with the primary antibody diluted in 5% goat
serum and then with the secondary antibody in 1% goat serum. The sections were
stained with streptavidin-horseradish peroxidase, DAB, and hematoxylin (as a
nuclear counterstain).
Frozen tissue sections (4 m) were air dried overnight and fixed for 7 min in
acetone at room temperature. The slides were incubated with primary antibody
for 1 h at room temperature and then with horseradish peroxidase-labeled goat
anti-rat immunoglobulin antiserum (Santa Cruz). Color development was ob-
tained with 0.4 mg of aminoethyl carbazole per ml and 0.02% H2O2 as a chro-
mogen.
Distribution and pharmacokinetics of topotecan. Mice were injected with 2
mg of topotecan (GlaxoSmithKline) per kg via the tail vein. Blood was obtained
by either retro-orbital puncture or cardiac puncture. Urine, bile, and selected
tissues were collected. Samples were processed as previously described (18, 39,
47). The pharmacokinetic parameters of topotecan were estimated by using the
software NONMEM (6). Data from Mrp4/ and Mrp4/ mice were modeled
simultaneously with a two-compartment model (18). Nonlinear mixed-effects
modeling was used to determine whether the absence of Mrp4 was a significant
covariate of the topotecan pharmacokinetic parameters (16).
Intracellular accumulation of topotecan. Saos-2 cells containing either
pcDNA3 or pcDNA3-MRP4 were plated (105 cells per well) in a six-well plate.
At 70% confluence, the cells were washed with phosphate-buffered saline, and
the medium was replaced with fresh medium containing topotecan but no anti-
biotics or phenol red. At the time points designated in the Results, the medium
was removed, the cells were washed twice with ice-cold phosphate-buffered
saline, and ice-cold water was added to lyse the cells. Topotecan was extracted
from the lysate with methanol and assayed by high-pressure liquid chromatog-
raphy (P. J. Houghton, G. S. Germain, F. C. Harwood, J. D. Schuetz, C. F.
Stewart, E. Buchdunger, and P. Traxler, submitted for publication). Values were
normalized to total protein content by using bovine serum albumin as a standard
(8).
Cytotoxicity. Cells expressing human MRP4 (Saos 2-MRP4) or the vector only
(Saos 2-pcDNA3.1) (2) were cultured in 96-well plates in medium without phe-
nol red or antibiotics. An aqueous stock solution of topotecan was diluted with
medium, added to the wells, and mixed. The cells were incubated for 6 h, the
medium was removed, and the cells were washed and grown to 90% confluence.
Within each cell line, the viability of treated and untreated cells was compared
by a [4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) (Sigma)
or Alamar Blue (BioSource) assay (4, 10).
Vesicular transport assays. Vesicle-containing fractions prepared from cells
engineered to express Mrp4 (2) were incubated with 15 M 3H-labeled estradiol-
17-glucuronide (PerkinElmer) and various amounts of topotecan for 5 min at
37°C, essentially as described previously (49).
Microdialysis. The surgical procedures, implantation of the cannula and mi-
crodialysis probe, and method of assaying topotecan concentration in the brain
have been described elsewhere (M. Leggas, Y. Zhuang, J. Welden, Z. Self, C. M.
Waters, and C. F. Stewart, submitted for publication).
Statistical analysis. Data were analyzed by two-way analysis of variance with
Bonferroni adjustment for multiple pairwise comparisons with the SigmaStat
package (SPSS Science).
RESULTS
Generation of Mrp4-deficient mice. Both the human and
mouse MRP4 genes contain 31 exons (23). We targeted exon
27, which encodes a region between the conserved Walker A
and B motifs that appears to be essential for communication
between these motifs (12) and that facilitates ATP hydrolysis.
The Mrp4 gene was disrupted in murine ES cells by replacing
exon 27 with a neomycin resistance cassette by homologous
recombination (Fig. 1a). To ensure disruption of Mrp4 expres-
sion, we used an oligonucleotide primer that had three in-
frame stop codons engineered into exon 27. Quantitative re-
verse transcription-PCR analysis revealed 100-fold less Mrp4
mRNA in the Mrp4/ mouse kidney than in the Mrp4/
mouse kidney. Disruption of Mrp4 in ES cells was confirmed by
Southern blot analysis (not shown), and disruption of the Mrp4
allele in mice was shown by PCR analysis of tail DNA (Fig. 1a).
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FIG. 1. Targeted disruption of the Mrp4 locus causes loss of renal Mrp4 expression. (a) Targeting construct design and locus. Xho, XhoI
cleavage site; B, BamHI cleavage site; E, EcoRI cleavage site; Sal, SalI cleavage site; neo, position of neomycin phosphotransferase gene; TGA,
stop codons engineered into exon 27 (see text). Exon numbers are shown. (b) Representative Mrp4 genotype analysis of Mrp4 wild-type,
heterozygous, and nullizygous mice. (c) Immunoblot with anti-mouse Mrp4 shows Mrp4 expression in kidney membranes from Mrp4/ and
Mrp4/ but not Mrp4/ mice. (d) Immunohistochemical analysis of Mrp4 expression in paraffin-embedded kidneys from Mrp4/ and Mrp4/
mice. The murine anti-Mrp4 polyclonal antiserum Mrp4-mp was used in panels 1 and 2. The monoclonal anti-Mrp4 antibody M4I-10 was used in
panels 3 and 5. The inset (panel 4) shows the proximal tubules at greater magnification.
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We tested the effect of Mrp4 gene disruption on renal ex-
pression of Mrp4 protein. In immunoblot analyses of crude
membrane fractions, loss of one allele resulted in a 50% re-
duction in immunoreactive Mrp4, and deletion of both alleles
resulted in complete loss of expression (Fig. 1c). No additional
intact or truncated Mrp4 protein was detected on the Mrp4/
immunoblot with either the polyclonal antibody Mrp4-mp or
the monoclonal antibody M4I-10. Immunohistochemical anal-
ysis with these two new anti-Mrp4 antibodies detected Mrp4 in
the apical membranes of the proximal renal tubules (Fig. 1d,
panels 1, 3, and 4), in agreement with a previous report that
human MRP4 is localized to the proximal renal tubules (44).
The offspring of crossbred Mrp4/ mice had a normal Men-
delian ratio, indicating that Mrp4 is not required for normal
development. Mrp4/ mice bred normally, produced normal-
size litters with the expected male-female ratio, and gained
weight normally for as long as 15 months. Microscopic histol-
ogy of brain, liver, lung, and kidney tissues revealed no abnor-
malities in Mrp4/ mice. In standard clinical assays, the mice
had normal hemoglobin concentrations and packed-cell vol-
umes, and liver function values (serum transaminases, alkaline
phosphatase, and total bilirubin) were within normal limits.
Notably, the absence of Mrp4 resulted in no apparent defects
in renal function: serum concentrations of urea, nitrogen, cre-
atinine, total protein, and electrolytes were within normal lim-
its.
Topotecan excretion in the absence of Mrp4. The abundant
renal expression of Mrp4 and the renal elimination of topote-
can (18, 44, 48) prompted us to evaluate the elimination of
intravenously administered topotecan in six mice of each ge-
notype (Mrp4/ and Mrp4/). The mice were given an in-
jection of 2 mg of topotecan per kg via the tail vein, and their
plasma topotecan concentrations were measured at intervals.
Topotecan elimination followed the expected biphasic pattern
(48) in Mrp4/ and Mrp4/ animals. At 6 h, the plasma
concentration of both forms of topotecan (hydroxy acid and
lactone) was 50% higher in the Mrp4/ than in the Mrp4/
animals. We developed a pharmacokinetic model based on the
topotecan elimination kinetics to predict differences between
the Mrp4/ and Mrp4/ animals in the tissue penetration of
topotecan. From this model, we estimated tissue penetration
rate constants of 0.35 in the Mrp4/ and 0.65 in the Mrp4/
animals. These rate constants predict more rapid drug pene-
tration into the tissues of the Mrp4/ animals, consistent with
the higher topotecan concentration observed in some tissues of
the Mrp4/ animals (see below). A similar concentration of
topotecan was present in the bile of the Mrp4/ and Mrp4/
mice 6 h postinjection. In contrast, the urine topotecan con-
centration was 36% lower in the Mrp4/ animals than in the
Mrp4/ animals at 6 h.
Mrp4 overexpression decreases topotecan accumulation
and toxicity. Although topotecan exists as an anion, it is not a
known substrate of Mrp4. Because of the decreased urine
concentration of topotecan in the Mrp4/ animals, we next
examined the ability of topotecan to inhibit Mrp4-mediated
transport of a known substrate. Membrane vesicles prepared
from cells engineered to express human MRP4 were incubated
with the radiolabeled substrate 2-estradiol-17-glucuronide,
and ATP-dependent transport was measured (48). Topotecan
inhibited MRP4-mediated transport of the substrate in a dose-
dependent manner (Fig. 2a). Accumulation of topotecan was
then compared in cells programmed to express human MRP4
or the empty vector (2). Cells overexpressing human MRP4
accumulated much less topotecan (Fig. 2b) and were much less
sensitive to topotecan (estimated 50% inhibitory concentra-
tion, 1 versus 5 M; P  0.05). Therefore, Mrp4 can confer
resistance to topotecan, as also shown by cell viability assays
(Fig. 2c). The decreased intracellular concentration of topote-
can in MRP4-overexpressing cells is consistent with the known
expression of MRP4 in the plasma membrane (Fig. 2d). These
results indicate that topotecan is an Mrp4 substrate and that its
overexpression contributes to topotecan resistance.
Mrp4 expression in the choroid plexus and cerebral vascu-
lature. After systemic administration of 2 mg of topotecan/kg,
the whole-brain concentration of topotecan was almost six
times as high in the Mrp4/ mice as in the Mrp4/ mice (Fig.
3a). Immunoblot analysis demonstrated the presence and ab-
sence of Mrp4 in whole-brain protein extracts from Mrp4/
and Mrp4/ mice, respectively (Fig. 3b). Because of recent
reports that some Mrp4 substrates are removed from the brain
by an organic anion transporter, we assessed whether Mrp4 is
expressed in the choroid plexus. We compared the level of
Mrp4 expression in choroid plexus lysate with that in kidney
crude membrane fractions by immunoblot with an antibody to
human Mrp4 (Mrp4-hp) (1, 2) that cross-reacts with mouse
Mrp4 and a newer antibody to the extreme C terminus of
mouse Mrp4 (Mrp4-mp). Both antibodies detected Mrp4 in
the kidney and choroid plexus of Mrp4/ mice but not
Mrp4/ animals (Fig. 4a).
To estimate the relative expression of Mrp4 in the choroid
plexus compared to the kidney, we loaded different amounts of
choroid plexus lysate on the gel and compared the intensity of
the resulting bands with that of a band representing a known
amount of kidney membrane. The choroid plexus appeared to
contain at least four to five times as much Mrp4 as the kidney
(Fig. 4b) in this rough estimate. In the choroid plexuses of
Mrp4/ and Mrp4/ animals, we found at both low (Fig. 4c,
panels 1 and 3, respectively) and high (Fig. 4c, panel 2) mag-
nification that Mrp4 was localized to the basolateral surface of
the choroid plexus. We then used the anti-Mrp4 monoclonal
antibody to identify Mrp4 expression in the choroid plexus
from a different strain of mouse (FVb), from rats, and from
humans (Fig. 4d, panels 1 to 4). In all three species, Mrp4 was
localized to the basolateral membrane of the choroid plexus, a
location that would allow it to restrict brain penetration of
topotecan.
The comparatively high topotecan levels in the brain of
Mrp4/ mice could also reflect the absence of Mrp4 expres-
sion in brain capillaries. Cultured brain capillary endothelium
shows anion transport activity (5, 25, 41). We used the mono-
clonal anti-Mrp4 antibody to evaluate Mrp4 expression in
brain capillaries in frozen and in paraffin-embedded tissue
sections. Mrp4 was expressed only in the capillaries of Mrp4/
animals (Fig. 5a). To localize Mrp4, we examined the cross-
section of a brain capillary from a mouse (Fig. 5b, panel 1) and
a rat (Fig. 5b, panel 2) at high magnification. In both, the
anti-Mrp4 antibody stained the apical membrane of the endo-
thelial cells of brain capillaries). Therefore, Mrp4 is expressed
in the basolateral membrane of the choroid plexus epithelial
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cells and in the luminal side of brain capillaries, consistent with
Mrp4’s restricting the brain penetration of its substrates.
Restriction of CSF accumulation of topotecan by Mrp4. If
Mrp4 in the basolateral epithelium of the choroid plexus and in
the brain capillaries restricts the brain penetration of system-
ically administered topotecan, we would predict a greater CSF
concentration of topotecan in Mrp4/ animals after adminis-
tration of topotecan. We stereotactically inserted cannulas into
the lateral ventricles of mice and obtained CSF samples by
microdialysis at 15-min intervals over a 3-h period after injec-
tion of 2 mg of topotecan/kg via the tail vein. The CSF topo-
tecan concentration of Mrp4/ mice was almost 10-fold that
of Mrp4/ mice at each time point (Fig. 6a). These results
directly demonstrate that Mrp4 in the choroid plexus and brain
capillaries limits the passage of topotecan from the blood into
the CSF. We propose models depicting how Mrp4 restricts
brain penetration by topotecan in the choroid plexus (Fig. 6b)
and in the brain capillaries (Fig. 6c).
DISCUSSION
Our development of an Mrp4-nullizygous mouse allowed us
to demonstrate that Mrp4 limits the brain penetration of sub-
strate drugs by exerting strong anionic transport activity in the
blood-brain and blood-CSF barriers. Mrp4 functions at two
levels, protecting cells from cytotoxic accumulation of topote-
can and restricting topotecan penetration into the brain. Mrp4
expression was demonstrated in the basolateral membrane of
the choroid plexus epithelium and in the brain capillary endo-
thelium. As a proof of concept, we showed in vivo that Mrp4
effectively limits the movement of topotecan from the blood
into the CSF. These findings suggest that Mrp4 functions to
inhibit the movement of other toxic anionic compounds into
the brain from the blood. Because Mrp4 transports a variety of
important chemotherapeutic substrates (1, 7, 34, 37, 44, 45),
inhibition of Mrp4-mediated transport might facilitate the
brain penetration of therapeutic organic anions used to treat a
number of malignancies and other diseases.
The endothelial cells in the lumen of brain capillaries form
tight junctions that restrict the penetration of large, strongly
hydrophilic compounds (32). These cells also have efflux trans-
porters for cationic compounds (e.g., Pgp) and organic anions
(5, 25, 41). It is noteworthy that many of the endogenous
anions reportedly effluxed by cultured brain capillary endothe-
FIG. 2. Topotecan is an Mrp4 substrate. (a) Transport of the Mrp4 substrate estradiol-17-glucuronide into membrane vesicles prepared from
Saos-2 cells engineered to express Mrp4 (13) in the presence of various concentrations of topotecan. (b) The intracellular accumulation of
topotecan was assayed in Saos-2 cells transfected with empty vector or stably expressing human MRP4 at the indicated times after treatment. (c)
Topotecan sensitivity of the cells shown in panel d, shown as percent cell viability. Localization of Mrp4 in Saos-2 cells stably expressing Mrp4 (d)
or transfected with empty vector (e). Bars represent 1 standard deviation.
FIG. 3. Topotecan concentration in the brain is higher in the ab-
sence of Mrp4. (a) Mean ( standard deviation) concentration of
topotecan in the brains of six Mrp4/ (open bars) and six Mrp4/
(solid bars) mice 15 min and 6 h after intravenous injection of 2 mg of
topotecan/kg. (b) Equal samples of total brain protein (10 g) from
Mrp4/ and Mrp4/ animals were fractionated by polyacrylamide
gel electrophoresis and treated with the monoclonal anti-Mrp4 anti-
body M4I-10.
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FIG. 4. Mrp4 is highly expressed in the basolateral membrane of the choroid plexus in multiple species. (a) Detection of Mrp4 in the choroid
plexus (CP) and kidney of Mrp4/ mice by immunoblot analysis with two different anti-Mrp4 antibodies. 3T3, NIH 3T3 cells transfected with the
Mrp4 expression vector or empty vector served as positive and negative controls, respectively. (b) Mrp4 was more abundant in the choroid plexus
than in the kidney of Mrp4/ mice, as shown by immunoblot analysis with polyclonal anti-mouse Mrp4 (Mrp4-mp). (c) Immunohistochemical
localization of Mrp4 in choroid plexus epithelial cells from Mrp4/, Mrp4/, and Mrp4/ animals with the murine polyclonal Mrp4 antiserum
(Mrp4-mp). The magnification is indicated above each panel. (d) Mrp4 expression detected in the choroid plexus from an FVB mouse, rat, and
human (panels 1 to 4, respectively) with the anti-Mrp4 monoclonal antibody (M4I-10).
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lial cells are Mrp4 substrates (taurocholate, dehydroepiandro-
sterone 3-sulfate, 2-estradiol-17-glucuronide, and estrone sul-
fate) and that the anions are transported into the capillary
lumen (17, 19, 20). The expression of Mrp4 in the lumen of
brain capillaries is compatible with the premise that Mrp4
protects the brain by restricting the movement of cytotoxic
organic anions out of the capillaries.
The choroid plexuses within the lateral, third, and fourth
ventricles form a barrier between the blood and the ventricular
CSF and are morphologically indistinguishable in Mrp4/ and
Mrp4/ mice. Organic anion transporters have been identi-
fied in the apical and basolateral membranes of the choroid
plexus epithelial cells (24). Basolateral localization places
Mrp4 in proximity to the fenestrated capillaries of the choroid
plexus, where it can prevent uptake of anionic substances from
the blood. Mrp4 may also efflux toxic metabolites from the
brain. For example, 1-naphthol is a cytotoxic and genotoxic
compound whose glucuronide is effluxed from the choroid
plexus epithelium by an ABC-like transporter (40). The fact
that naphthol-glucuronide inhibits Mrp4 transport (44) sug-
gests that it is an Mrp4 substrate. Methotrexate is another
organic anion and Mrp4 substrate (19). Importantly, the trans-
port of intraventricularly injected methotrexate from the cho-
roid plexus into the blood is inhibited by probenecid, a re-
ported Mrp4 inhibitor (38, 44). Therefore, Mrp4 appears to
play a significant but heretofore unrecognized role in the CNS
penetration of some cytotoxins and therapeutic agents. More-
over, Bcrp (another efflux transporter of topotecan and meth-
otrexate) is undetectable in murine blood-brain barrier cells
(unpublished observation) and is thus unlikely to limit the
uptake of these substrates into the brain.
Mrp4’s ability to be expressed on either the basolateral or
apical membrane was anticipated, based upon previous immu-
nohistochemical analysis showing basolateral localization in
the prostate and apical localization in the kidney (21, 44), but
the biological importance of Mrp4’s unique ability to localize
apically or basolaterally was unknown. There are examples of
transporters that route to different surfaces in polarized cells;
however, among the Mrp (ABCC) subfamily of transporters
localization is to either the basolateral or apical membrane, but
not both. For instance, MRP1 is restricted to the basolateral
membrane in the choroid plexus and intestine, whereas MRP2
FIG. 5. Mrp4 is expressed in brain capillaries. (a) Frozen tissue sections prepared from the brains of Mrp4/ and Mrp4/ FVB mice were
treated with anti-Mrp4 monoclonal antibody. (b) Panel 1 shows a cross-section of wild-type mouse capillary, revealing red blood cells (asterisk),
surrounding capillary wall, and luminal Mrp4 staining (red); panel 2 shows a rat capillary, revealing interior red blood cells (asterisk). Arrows
indicate the capillary wall and the luminal endothelial cell Mrp4 staining (red). Magnifications are indicated to the left of the panels.
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is found on the apical membrane in the intestine and liver (26,
29).
Mrp4 is unique among the Mrp4 subfamily of ABC trans-
porters because its polarized expression is cell and tissue de-
pendent. In the kidney, proximal tubules, and brain capillary
endothelial cells, Mrp4 is routed apically, which orients it to
vectorially transport its substrates into the lumen. In contrast,
Mrp4’s basolateral location in the choroid plexus epithelium
allows it to exclude the entry of substrates into the CSF from
the blood. These differences have led us to speculate that the
asymmetrical localization of Mrp4 in polarized cells plays a
role in the transport of an important anionic substrate(s)
unique to these tissues. An example from the organic anion-
transporting polypeptides illustrates this possibility. Oatp2 is
expressed at the basolateral membrane in the liver but on the
apical membrane in the retina (13). Expression of Oatp2 in the
retina is postulated to involve the transport of unusual cationic,
amphiphillic retionoids (i.e., N-retinyl and N-retinylidene eth-
anolamine) into and out of retinal pigment epithelial cells.
Mrp4 localization and orientation in the choroid plexus and
capillaries suggest a role in the flux of important physiologic
anions from the brain or CSF into the blood. One candidate
substrate is prostaglandins. Prostaglandins have recently been
demonstrated to be Mrp4 substrates (31). Prostaglandins are
synthesized in the choroid plexus (15), undergo circadian vari-
ation (28), and are important in mediating the pain response
(33). An Mrp4-mediated efflux from the brain would be com-
patible with controlling prostaglandin levels.
In conclusion, we have shown that Mrp4 restricts the pene-
tration of the brain by the important CNS-active anticancer
agent topotecan. This function is linked to Mrp4’s dual roles in
the blood-CSF and blood-brain barriers. The ability of Mrp4 to
block the CNS entry of topotecan is closely linked to its specific
localization to either the apical or basolateral membrane. This
dual localization of Mrp4 may help to explain the difficulty in
identifying the anionic transporters in the CNS in vivo. Our
findings provide a new “molecular handle” by which we can
better understand not only the efflux of topotecan but also that
of other anionic therapeutic compounds whose limited CNS
penetration and decreased therapeutic effect may now be ex-
plained by the expression of Mrp4. Furthermore, our findings
illustrate that Mrp4 overexpression in tumor cells can limit
drug penetration and confer topotecan resistance. In total,
these findings have important therapeutic implications for the
treatment of CNS tumors, which express Mrp4, as well as for
therapies targeted toward the brain.
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